ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.

SPRY ARS Pharmaceuticals Inc

9,46
0,13 (1,39%)
Nach Börsenschluss
Zuletzt aktualisiert: 00:00:06
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
ARS Pharmaceuticals Inc SPRY NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,13 1,39% 9,46 00:00:06
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
9,35 8,94 9,51 9,46 9,33
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
30.4.202415:01GLOBEARS Pharmaceuticals Submits Response for neffy® (epinephrine..
03.4.202415:01GLOBEARS Pharmaceuticals Submits Response to FDA Complete..
21.3.202421:05GLOBEARS Pharmaceuticals Provides Business Update and Reports..
07.3.202422:05GLOBEARS Pharmaceuticals Reviews Recent Clinical Updates and..
07.3.202418:56EDGAR2Form 8-K - Current report
06.3.202415:01GLOBEARS Pharmaceuticals to Participate in the Leerink Partners..
02.3.202402:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.2.202418:08EDGAR2Form 144 - Report of proposed sale of securities
26.2.202415:01GLOBEARS Pharmaceuticals announces neffy® meets primary endpoints..
22.2.202415:01GLOBEARS Pharmaceuticals to Host Virtual neffy® Investor Day on..
20.2.202415:01GLOBEARS Pharma Announces Favorable Topline Results from Repeat..
05.2.202415:01GLOBEARS Pharmaceuticals to Present Positive Clinical Efficacy..
04.1.202422:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04.1.202422:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.11.202322:02EDGAR2Form 8-K - Current report
09.11.202322:00GLOBEARS Pharmaceuticals Reports Third Quarter 2023 Financial..
09.11.202317:02GLOBEARS Pharmaceuticals Announces Presentation of Clinical Data..
06.10.202315:57DJNARS Pharmaceuticals to Meet With FDA on Neffy Rejection
06.10.202315:03GLOBEARS Pharmaceuticals Announces Scheduling of a Type A Meeting..
03.10.202315:03GLOBESingle and Repeat Dose Clinical Study of neffy (epinephrine..
25.9.202322:17EDGAR2Form 8-K - Current report
20.9.202316:20DJNARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy..
20.9.202312:30DJNARS Pharmaceuticals Shares Sink Premarket as FDA Rejects..
20.9.202312:05EDGAR2Form 8-K - Current report
20.9.202304:49GLOBEFDA Issues Complete Response Letter for neffy® (epinephrine..
01.9.202322:15EDGAR2Form SC 13D/A - General statement of acquisition of..
10.8.202322:08EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10.8.202322:05EDGAR2Form 8-K - Current report
10.8.202322:00GLOBEARS Reports Second Quarter 2023 Financial Results and..
29.6.202303:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.6.202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28.6.202322:32EDGAR2Form 8-K - Current report
20.6.202314:00GLOBEARS Pharmaceuticals Announces PDUFA Date Extension for..
15.5.202315:00GLOBEARS Pharmaceuticals Highlights Progress and Reports First..
12.5.202314:55DJNARS Pharmaceuticals Soar 68% in Premarket Trading as FDA..
12.5.202301:01GLOBEFDA Advisory Committee Votes in Support of Favorable..
09.5.202315:10GLOBEARS Pharmaceuticals Announces Availability of Briefing..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock